NSCLC

Test Your Knowledge
Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?
08/03/2021
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of...
08/03/2021
Oncology
News
EGFR-TKIs Exhibit Safety and Tolerability in Patients with NSCLC
07/22/2021
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in combination with chemotherapy were studied for safety variables in patients with advanced non-small-cell lung cancer (NSCLC) and sensitive EGFR mutations.
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in combination with chemotherapy were studied for safety variables in patients with advanced non-small-cell lung cancer (NSCLC) and sensitive EGFR mutations.
Epidermal growth factor...
07/22/2021
Oncology
News
Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
02/15/2021
02/15/2021
Journal of Clinical Pathways
News
Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings
12/17/2020
12/17/2020
Journal of Clinical Pathways
Research in Review
Aggressive Care Associated With Poorer Outcomes for Patients With NSCLC at End of Life
06/14/2017
JCP Editors
Aggressive care in the last month of life for patients with non–small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care. Patients with advanced NSCLC who are nearing...
Aggressive care in the last month of life for patients with non–small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care. Patients with advanced NSCLC who are nearing...
...
06/14/2017
Journal of Clinical Pathways
Research in Review
Adjuvant Chemo After Surgery Improves OS in Patients With NSCLC and Brain Metastasis
06/03/2017
JCP Editors
Patients with non-small cell lung cancer (NSCLC) and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival (OS) after thoracic surgery and systemic chemotherapy, according to research...
Patients with non-small cell lung cancer (NSCLC) and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival (OS) after thoracic surgery and systemic chemotherapy, according to research...
...
06/03/2017
Journal of Clinical Pathways
Research in Review
Aggressive Care Associated With Poorer Outcomes for Patients With NSCLC at End-of-Life
05/26/2017
JCP Editors
Aggressive care within the last month of life for patients with non-small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care, according to new research. ----- Related...
Aggressive care within the last month of life for patients with non-small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care, according to new research. ----- Related...
...
05/26/2017
Journal of Clinical Pathways
Research in Review
Study Shows Low Adherence to Guidelines for Brain Imaging in NSCLC Patients
10/28/2015
JCP Editors
As part of the Choosing Wisely® campaign, the Society of Thoracic Surgeons developed a list of tests and procedures that they consider to be ordered more often than necessary. Included in this list is the use of...
As part of the Choosing Wisely® campaign, the Society of Thoracic Surgeons developed a list of tests and procedures that they consider to be ordered more often than necessary. Included in this list is the use of...
As...
10/28/2015
Journal of Clinical Pathways
Research in Review
Improved Outcomes for NSCLC Patients with Immunotherapy versus Chemotherapy
10/15/2015
JCP Editors
Researchers from the University of Texas-Southwest Medical Center compared the immunotherapy drug nivolumab with a commonly used chemotherapy drug and found that it improved overall survival with...
Researchers from the University of Texas-Southwest Medical Center compared the immunotherapy drug nivolumab with a commonly used chemotherapy drug and found that it improved overall survival with...
...
10/15/2015
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use